Assenagon Asset Management
PTCT icon

Assenagon Asset Management’s PTC Therapeutics PTCT Stock Holding History

Assenagon Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$563K Sell
6,899
-54,498
-89% -$3.94M ﹤0.01% 1057
2026
Q1 		$4.18M Buy
61,397
+7,227
+13% +$512K 0.01% 619
2025
Q4 		$4.11M Sell
54,170
-53,478
-50% -$3.89M 0.01% 684
2025
Q3 		$6.61M Sell
107,648
-523,974
-83% -$27.3M 0.01% 564
2025
Q2 		$30.8M Buy
631,622
+293,662
+87% +$13.9M 0.05% 293
2025
Q1 		$17.2M Sell
337,960
-101,710
-23% -$5.08M 0.03% 344
2024
Q4 		$19.8M Sell
439,670
-52,794
-11% -$2.26M 0.03% 357
2024
Q3 		$18.3M Buy
492,464
+119,637
+32% +$4.01M 0.03% 371
2024
Q2 		$11.4M Buy
372,827
+66,596
+22% +$2.16M 0.03% 408
2024
Q1 		$8.91M Buy
306,231
+63,570
+26% +$1.78M 0.02% 459
2023
Q4 		$6.69M Buy
242,661
+190,628
+366% +$4.36M 0.02% 556
2023
Q3 		$1.17M Buy
52,033
+46,247
+799% +$1.72M ﹤0.01% 1008
2023
Q2 		$235K Sell
5,786
-13,291
-70% -$650K ﹤0.01% 1262
2023
Q1 		$924K Sell
19,077
-153,861
-89% -$7.03M ﹤0.01% 1073
2022
Q4 		$6.6M Buy
172,938
+43,716
+34% +$1.82M 0.02% 473
2022
Q3 		$6.49M Buy
129,222
+119,593
+1,242% +$5.86M 0.02% 429
2022
Q2 		$386K Sell
9,629
-101,279
-91% -$3.55M ﹤0.01% 1278
2022
Q1 		$4.14M Buy
110,908
+91,723
+478% +$3.53M 0.01% 582
2021
Q4 		$764K Buy
+19,185
New +$734K ﹤0.01% 1116
2021
Q2 		– Sell
-72,400
Closed -$3.43M – 1370
2021
Q1 		$3.43M Hold
72,400
– – 0.01% 591
2020
Q4 		$4.42M Sell
72,400
-194,900
-73% -$11.5M 0.02% 371
2020
Q3 		$12.5M Buy
+267,300
New +$13.2M 0.07% 164
2020
Q1 		– Sell
-102,737
Closed -$4.93M – 954
2019
Q4 		$4.93M Buy
+102,737
New +$4.37M 0.03% 245

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Assenagon Asset Management's PTCT Position: Q2 2026 in Review

Assenagon Asset Management reduced its PTC Therapeutics (PTCT) stake by 89% in Q2 2026, selling an estimated $3.94M and leaving 6,899 shares worth $563K. The position accounts for ﹤0.01% of the portfolio, ranked #1057.

Assenagon Asset Management first reported a position in PTCT in Q4 2019 and has held it in 23 quarters since. The position peaked at $30.8M in Q2 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Assenagon Asset Management held 6,899 shares of PTC Therapeutics worth $563K as of Q2 2026.
  • Assenagon Asset Management sold 54,498 PTC Therapeutics shares in Q2 2026, an estimated $3.94M.
  • PTC Therapeutics made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #1057 holding.
  • Assenagon Asset Management first reported a position in PTC Therapeutics in Q4 2019 and has held it in 23 quarters since.
  • Assenagon Asset Management's PTC Therapeutics position peaked at $30.8M in Q2 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.